Moffitt Cancer Center Advances Patient Standard of Care by Introducing Needleless Blood Draws
Moffitt is the first cancer center and the first hospital in Florida to use this new technology
Tampa, Florida -- Moffitt Cancer Center has adopted a new needle-free method of blood collection for patients in treatment who often need to undergo repeated needle sticks in a day, becoming the first cancer center in Florida to offer this pain-free technology as part of its world-class cancer care.
In its continuing efforts of being at the forefront of innovation, last year the cancer center piloted the needle-free PIVO™ procedure from vascular access technology pioneer Velano Vascular. Since then, thousands of needle sticks have been avoided.
“A needle stick may seem inconsequential, but when repeated numerous times a day on a cancer patient with fragile veins who already carries a significant physical and emotional burden, it can be traumatic,” said Jane Fusilero, vice president and chief nursing officer at Moffitt. “This one seemingly small change, to remove the needle from blood collection, is making an enormous difference to our patients and team members alike. What used to be a dreaded, painful experience because of needles is now met with relief and smiles — a transformation that is positive and should be the expectation for patients fighting this disease.”
Moffitt is adopting this novel procedure across its inpatient population in an effort to bring more humanity to a common yet critical medical procedure, and to do so through a safer alternative to drawing blood from central lines and ports.
“This is a dramatic improvement in how a cancer center can approach vein access with our patients,” said Fusilero. “By shifting collection with this novel needle-free procedure to a traditional peripheral IV line, we’ve been able to significantly enhance our already high quality of care — eliminating pain and discomfort, optimizing practice efficiency, and reducing risk — all while enhancing the patient experience.”
This new standard of care enables what is known as one-stick hospitalization, a practice now in place at many leading health systems around the country. Moffitt is adopting the standard in its fight against cancer.
Related news
-
Med Tech Outlook: Top Medical Ventilator Solution Providers 2021
Accurate breath analysis is key for diagnosis and assessment of pulmonary illnesses. Breath analysis is an important evaluation tool to support respiratory therapists and pulmonologists in the diagnosis and treatment of varying respiratory illnesses. Unfortunately, moisture is an impediment to successful breath analysis. Moisture in breath samples can adversely impact the accuracy of breath analysis and damage devices. As such, respiratory device providers seek robust solutions that reduce moisture from breath...
-
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, offering the NanoTherm Therapy System for the treatment of brain tumors, supports World Brain Tumor Day on June 8th, 2021 and informs about various virtual patient events to raise awareness for this devastating disease. “Though rare compared to other types of cancers, brain tumors, especially glioblastomas, are a devastating and mostly fatal disease. Despite...
-
Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and the University of California, San Francisco (UCSF) today announced they have formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies. Under the agreement, Thermo Fisher will build and operate a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing and collaboration center in leased space on UCSF`s Mission Bay campus, which includes biomedical research facilities...
-
MediPines AGM100 Voted as Finalist in Medical Design Excellence Awards, MDEA 2021
We are pleased to announce that MediPines AGM100, a non-invasive pulmonary gas exchange analyzer, was selected as a finalist in the 2021 Medical Design Excellence Awards (MDEA). The MDEAs is the premier design competition in the MedTech industry organized by MD+DI and recognizes the significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. “On behalf of the entire team at MediPines we are honored to be recognized by the MDEA judges...
-
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population. Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet on February 4, 2020 Data from the ACTT-2 clinical trial resulted in the FDA granting emergency use authorisation for...
Customer comments
No comments were found for Moffitt Cancer Center Advances Patient Standard of Care by Introducing Needleless Blood Draws. Be the first to comment!